There are currently 90 clinical trials in Glendale, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Glendale Adventist Medical Center, Behavioral Research Specialists, LLC, Glendale Memorial Hospital and Health Center and Global Research Management. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma
NCT06223048
Recruiting
The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Open Angle Glaucoma (POAG).
Gender:
ALL
Ages:
22 years and above
Trial Updated:
07/29/2024
Locations: Global Research Management, Glendale, California
Conditions: Primary Open Angle Glaucoma
Register for Updates
A Study of AMDX-2011P in Participants With Alzheimer's Disease
NCT06514001
Recruiting
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with Alzheimer's Disease (AD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2024
Locations: Global Research Management, Glendale, California
Conditions: Alzheimer Disease
Register for Updates
Study of ALTO-300 in MDD
NCT05922878
Recruiting
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/05/2024
Locations: Site 217, Glendale, California
Conditions: Major Depressive Disorder
Register for Updates
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT05168566
Recruiting
This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: OPN Healthcare, Inc., Glendale, California
Conditions: Non-small Cell Lung Cancer
Register for Updates
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies
NCT04152499
Recruiting
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types: Triple negative breast cancer Epithelial ovarian cancer Non-small cell lung cancer Gastric adenocarcinoma/Gastroesophageal junction adenocarcinoma Small cell lung can... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Los Angeles Hematology Oncology Medical Group, Glendale, California
Conditions: Gastric Adenocarcinoma, Breast Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Epithelial Ovarian Cancer, Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma
Register for Updates
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
NCT05797896
Recruiting
An observational study to investigate the natural history and evaluate biomarkers of participants with geographic atrophy secondary to age-related macular degeneration
Gender:
All
Ages:
65 years and above
Trial Updated:
04/08/2024
Locations: Global Research Management, Glendale, California
Conditions: Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration, Macular Atrophy, Retinal Degeneration, Eye Diseases
Register for Updates
A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium
NCT05456425
Recruiting
The objective is to evaluate the safety and efficacy of low dose and high dose CBT-001 eye drop dosed twice daily for 24 months compared to vehicle in reducing conjunctival hyperemia and preventing pterygium progression in eyes with pterygia.
Gender:
All
Ages:
12 years and above
Trial Updated:
03/29/2024
Locations: Global Research Mangement, Glendale, California
Conditions: Pterygium
Register for Updates
Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula
NCT04884256
Recruiting
STUDY DESIGN: Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. Duration of Treatment: 4 weeks of study treatment with 4 weeks follow-up observations. Control: Vehicle for CBT-004 (hereafter referred to as Vehicle). Masking: Subjects, Investigators, Study Monitors and the Independent Image Reading Center are all masked to the study medications. Dosage/Dose regimen: One drop of the assigned study medication will be administered in the study eye... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/25/2024
Locations: Global Research Management, Glendale, California
Conditions: Pinguecula
Register for Updates
LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC
NCT04759664
Recruiting
The study evaluates the efficacy and safety of two strengths of LUT014 Gel topically applied once a day for 4 weeks, compared to placebo, in metastatic colorectal cancer (mCRC) patients who developed Grade 2 or non-infected Grade 3 EGFRI induced acneiform lesions
Gender:
All
Ages:
18 years and above
Trial Updated:
10/05/2023
Locations: Innovative Clinical Research Institute, Glendale, California
Conditions: EGFRI Induced Acneiform Lesions
Register for Updates
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
NCT05485974
Recruiting
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/12/2023
Locations: The Oncology Institute of Hope and Innovation, Glendale, California
Conditions: Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas, Colon Cancer, Solid Tumor, Cancer
Register for Updates
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
NCT05218044
Recruiting
Cryoablation or tumor freezing is a percutaneous, office-based procedure that is emerging as a minimally invasive, cost-effective alternative to surgery that is currently being evaluated in clinical trials for the management of for early-stage invasive breast cancer. The investigator will also evaluate the potential of cryoablation as a minimally invasive alternative to surgery for small areas of DCIS by examining its ability to achieve complete ablation of DCIS within the targeted cryoablation... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/02/2023
Locations: Office of Dennis R. Holmes, M.D., F.A.C.S., Glendale, California
Conditions: Ductal Carcinoma in Situ
Register for Updates
Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Molecular Testing Panel in the Community Setting ("DINOSAur")
NCT05692466
Recruiting
To prospectively identify cancer patients whose tumors express specific molecular markers targeted by therapeutic agents from a comprehensive molecular test, for the purpose of selecting the most clinically appropriate treatment in a pragmatic two arm trial.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/01/2023
Locations: Adventist Health Glendale, Glendale, California
Conditions: Stage III Solid Tumors, Stage IV Solid Tumors
Register for Updates